Abstract
We have previously shown that the Jak2 tyrosine kinase is activated in Bcr-Abl positive cell lines and blood cells from CML blast crisis patients by tyrosine phosphorylation. We are searching for downstream targets of Jak2 in Bcr-Abl positive cells. It is known that c-Myc expression is required for the oncogenic effects of Bcr-Abl, and that over-expression of c-Myc complements the transformation defect of the Bcr-Abl SH2 deletion mutant. Moreover, the Bcr-Abl SH2 deletion mutant and an Abl C-terminal deletion mutant are deficient in activating c-Myc expression. Since the Jak2 binds to the C-terminal domain of Bcr-Abl and optimal Jak2 activation requires the SH2 domain, we tested whether Jak2 was involved in c-Myc protein induction by Bcr-Abl. We treated the 32Dp210 Bcr-Abl cells with the Jak2 specific tyrosine kinase inhibitor, AG490, and found that this drug, like the Abl tyrosine kinase inhibitor STI-571, inhibited c-Myc protein induction by Bcr-Abl. Treatment of 32Dp210 Bcr-Abl cells with AG490 also inhibited c-MYC RNA expression. It is also known that c-Myc protein is a labile protein that is increased in amounts in response to various growth factors by a mechanism not involving new Myc protein formation. Treatment of 32Dp210 Bcr-Abl cells with both the proteasome inhibitor MG132 and AG490 blocked the reduction of the c-Myc protein observed by AG490 alone. An adaptor protein SH2-Bβ is involved in the enhancement of the tyrosine kinase activity of Jak2 following ligand/receptor interaction. In this regard we showed that the Jak2/Bcr-Abl complex contains SH2-Bβ. Expression of the SH2-Bβ R555E mutant in 32Dp210 Bcr-Abl cells reduced c-Myc expression about 40% compared to a vector control. Interestingly, we found the reduction of the c-Myc protein in several clones of dominant-negative (DN) Jak2 expressing K562 cells correlated very well with the reduction of tumor growth of these cells in nude mice as compared to vector transfected K562 cells. Both STI-571 and AG490 also induced apoptosis in 32Dp210 cells. Of interest, IL-3 containing medium reversed the STI-571 induced apoptosis of 32Dp210 cells but did not reverse the induction of apoptosis by AG490, which strongly supports the specificity of the inhibitory effects of AG490 on the Jak2 tyrosine kinase. In summary, our findings indicate that Jak2 mediates the increase in c-Myc expression that is induced by Bcr-Abl. Our results indicate that activated Jak2 not only mediates an increase of c-MYC RNA expression but also interferes with proteasome-dependent degradation of c-Myc protein.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Afar DEH, Goga A, McLaughlin J, Witte ON, Sawyers CL . 1994 Science 264: 424–426
Besancon F, Afti A, Gespach C, Cayre YE, Bourgeade M-F . 1998 Proc. Natl. Acad. Sci. USA 95: 8081–8086
Carlesso N, Frank DA, Griffin JD . 1995 J. Exp. Med. 183: 811–820
Chai SK, Nichols GL, Rothman PB . 1997 J. Immunol. 159: 4720–4728
Chaturvedi P, Sharma S, Reddy EP . 1997 Mol. Cell. Biol. 17: 3295–3304
Ciechanover A, DiGiuseppe JA, Bercovich B, Orian A, Richter JD, Schwartz AI, Brodeur GM . 1991 Proc. Natl. Acad. Sci. USA 88: 139–143
Danial NN, Losman JA, Lu T, Yip N, Krishmnan K, Krolewski J, Goff SP, Wang JYJ, Rothman PB . 1998 Mol. Cell. Biol. 18: 6795–6804
de Groot RP, Raaijmakers JAM, Lammers JWJ, Jove R, Koenderman L . 1999 Blood 94: 1108–1112
Deininger WM, Goldman JM, Melo JV . 2000 Blood 96: 3343–3356
Digicaylioglu M, Lipton SA . 2001 Nature 412: 641–647
Dijkers PF, van Dijk TB, de Groot RP, Raaijmakers JAM, Lammers JWJ, Koenderman L, Coffer PJ . 1999 Oncogene 18: 3334–3342
Flinn EM, Busch CMC, Wright APH . 1998 Mol. Cell. Biol. 18: 5961–5969
Gesbert F, Griffin JD . 2000 Blood 96: 2269–2276
Gross-Mesilaty S, Reinstein E, Bercovich B, Tobias KE, Schwartz AL, Kahana C, Ciechanover A . 1998 Proc. Natl. Acad. Sci. USA 95: 8058–8063
Guo JQ, Hirsch-Ginsberg CF, Xian YM, Stass SA, Champlin RE, Giralt Sa, McCredie KB, Campbell ML, Arlinghaus RB . 1993 Hematol. Pathol. 7: 91–106
Hann SR, Eisenman RN . 1984 Mol. Cell. Biol. 4: 2486–2497
Horita M, Andreu EJ, Benito A, Arbona C, Sanz C, Benet I, Prosper F, Fernandez-Luna JL . 2000 J. Exp. Med. 191: 977–984
Ilaria RL, Van Etten RA . 1996 J. Biol. Chem. 271: 31704–31710
Jones TR, Cole MD . 1987 Mol. Cell. Biol. 7: 4513–4521
Luscher B, Eisenman R . 1990 Genes Dev. 4: 2025–2035
La Rosa FA, Pierce JW, Sonenshein GE . 1994 Mol. Cell. Biol. 14: 1039–1044
Miyamoto N, Sugita K, Goi K, Inukai T, Lijima K, Tezuka T, Kojika S, Nakamura M, Kagami K, Nakazawa S . 2001 Leukemia 15: 1758–1768
Mui AL, Wakao H, Kinoshita T, Kitamura T, Miyajima A . 1996 EMBO J. 15: 2425–2433
Nieborowska-Skorska M, Wasik MA, Slupianek A, Salomoni P, Kitamura T, Calabretta B, Skorski T . 1999 J. Exp. Med. 189: 1229–1242
Okuda K, d'Andrea RA, Van Etten RA, Griffin JD . 1998 Blood 92: 3848–3856
Ramsay G, Stanton L, Schwab M, Littlewood T, Even G . 1986 Mol. Cell. Biol. 6: 4450–4457
Reuther JY, Reuther GW, Cortez D, Pendergast AM, Baldwin Jr AS . 1998 Genes Dev. 12: 968–981
Rui L, Carter-Su C . 1999 Proc. Natl. Acad. Sci. USA 96: 7172–7177
Rui I, Gunter DR, Herrington J, Carter-Su C . 2000 Mol. Cell. Biol. 20: 3168–3177
Salghetti SE, Kim SY, Tansey WP . 1999 EMBO J. 18: 717–726
Sambrook J, Fritch EF, Maniatias T . 1989 Molecular Cloning 2nd edn Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press
Sawyers CL, Callahan W, Witte ON . 1992 Cell 70: 901–910
Sears R, Nuckolls F, Haura E, Taya Y, Tamai K, Nevins JR . 2000 Genes Dev. 14: 2501–2514
Sherr CL . 1998 Genes Dev. 12: 3499–3511
Shui K, Halpern J, ten Hoeve J, Rao X, Sawyers CL . 1996 Oncogene 13: 247–254
Sillaber C, Gesbert F, Frank DA, Sattler M, Griffin JD . 2000 Blood 95: 2118–2125
Skorski T, Bellacosa A, Nieborowska-Skorska M, Majewski M, Martinez R, Choi JK, Trotta R, Wlodarski P, Perrotti D, Chan TO, Wasik MA, Tsichlis PN, Calabretta B . 1997 EMBO J. 16: 6151–6161
Socolovsky M, Fallon AEJ, Wang S, Brugnara C, Lodish HF . 1999 Cell 98: 181–191
Stewart MG, Litz-Jackson S, Burgess GS, Williamson EA, Leiboitz DS, Bosswell HS . 1995 Leukemia 9: 1499–1507
Takeshita T, Arita T, Higuchi M, Asao H, Endo K, Kuroda H, Tanaka N, Murata K, Ishii N, Sugamura K . 1997 Immunity 6: 449–457
Watanabe S, Itoh T, Arai K . 1996 J. Biol. Chem. 271: 12681–12686
Wilson-Rawls J, Xie S, Liu J, Laneuville P, Arlinghaus RB . 1996 Cancer Res. 56: 3426–3430
Xie S, Wang Y, Liu J, Sun T, Arlinghaus R . 2001 Oncogene 20: 6188–6195
Zhang Y, Turkson J, Carter-Su C, Smithgall T, Levitsky A, Kraker A, Krolewski JJ, Medveczky P, Jove R . 2000 J. Biol. Chem. 275: 24935–24944
Acknowledgements
These studies were supported by grants CA 49639 and CA 16672 from NIH. We thank Dr Christin Carter-Su (University of Michigan at Ann Arbor) for providing SH2-Bβ antibody and the SH2-Bβ constructs. We also thank Norvartis Pharmaceuticals for providing STI-571. We thank Dr Tomasz Skorskl (Temple University, Philadelphia, PA, USA) for providing 32D cells expressing Bcr-Abl and its mutants.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Xie, S., Lin, H., Sun, T. et al. Jak2 is involved in c-Myc induction by Bcr-Abl. Oncogene 21, 7137–7146 (2002). https://doi.org/10.1038/sj.onc.1205942
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.onc.1205942
Keywords
This article is cited by
-
The study of the impact of additional chromosomal aberrations and c-MYC and BCR::ABL1 genes amplification on CML patient’s characteristics: relation to haematological parameters and patient outcome
Egyptian Journal of Medical Human Genetics (2023)
-
C-Myc inhibition intensified the anti-leukemic properties of Imatinib in chronic myeloid leukemia cells
Molecular Biology Reports (2023)
-
MYC: a multipurpose oncogene with prognostic and therapeutic implications in blood malignancies
Journal of Hematology & Oncology (2021)
-
Heterogeneous BCR-ABL1 signal patterns identified by fluorescence in situ hybridization are associated with leukemic clonal evolution and poorer prognosis in BCR-ABL1 positive leukemia
BMC Cancer (2019)
-
Inhibition of YAP suppresses CML cell proliferation and enhances efficacy of imatinib in vitro and in vivo
Journal of Experimental & Clinical Cancer Research (2016)